Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo
- PMID: 7722313
Rat mammary adenocarcinoma 13762 expressing IFN-gamma elicits antitumor CD4+ MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo
Abstract
Rat adenocarcinoma 13762 was modified by transfection to express IFN-gamma, and the tumor-forming potential of cytokine-producing cells was found to be dramatically impaired. Animals resistant to inocula of IFN-gamma-modified tumor were resistant to subsequent challenge with unmodified 13762 tumor. Induced immunity was tumor specific in that syngeneic but non-cross-reactive tumor grew with normal kinetics in animals injected with IFN-gamma-producing 13762 tumor. Antitumor T cells were derived from animals primed with IFN-gamma-producing 13762 tumor and expanded into a cell line by coculture in vitro with IFN-gamma-producing 13762 cells. Anti-13762-gamma T cells were cytotoxic in vitro toward IFN-gamma-producing 13762 tumor and were not reactive with other syngeneic tumors or spleen B cells. Anti-13762-gamma T cells were determined to be CD4+ by Ab staining and flow cytometric analysis, and recognition of 13762-gamma in vitro was inhibited by anti-MHC class II Ab. Anti-13762-gamma T cells were not reactive in vitro with wild-type 13762 tumor unless treated with exogenous rIFN-gamma, which induced expression of cell surface MHC class II. However, adoptively transferred anti-13762-gamma T cells could effect regression of wild-type 13762 tumor or dramatically inhibit progressive growth in animals carrying significant tumor burden, and the antitumor phenotype did not require CD8+ T cells in vivo. These experiments demonstrate that although antitumor T cells elicited against cytokine-modified tumor may fail to demonstrate reactivity with unmodified tumor in vitro, antitumor properties may be manifest in vivo.
Similar articles
-
Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.Cell Immunol. 1997 May 25;178(1):79-90. doi: 10.1006/cimm.1997.1122. Cell Immunol. 1997. PMID: 9184701
-
Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.Cancer Gene Ther. 1998 Sep-Oct;5(5):313-20. Cancer Gene Ther. 1998. PMID: 9824051
-
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3435-43. doi: 10.1158/1078-0432.CCR-06-0165. Clin Cancer Res. 2006. PMID: 16740768
-
Transfection of interferon-gamma gene in animal tumors--a model for local cytokine production and tumor immunity.Semin Cancer Biol. 1992 Feb;3(1):43-6. Semin Cancer Biol. 1992. PMID: 1643293 Review.
-
Neoplastic cells that express low levels of MHC class I determinants escape host immunity.Semin Cancer Biol. 1994 Dec;5(6):419-28. Semin Cancer Biol. 1994. PMID: 7703441 Review.
Cited by
-
Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.J Virol. 2001 Nov;75(22):10593-602. doi: 10.1128/JVI.75.22.10593-10602.2001. J Virol. 2001. PMID: 11602701 Free PMC article.
-
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8633-8. doi: 10.1073/pnas.96.15.8633. Proc Natl Acad Sci U S A. 1999. PMID: 10411927 Free PMC article.
-
Extracellular traps released by antimicrobial TH17 cells contribute to host defense.J Clin Invest. 2021 Jan 19;131(2):e141594. doi: 10.1172/JCI141594. J Clin Invest. 2021. PMID: 33211671 Free PMC article.
-
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.J Exp Med. 2010 Oct 25;207(11):2469-77. doi: 10.1084/jem.20092450. Epub 2010 Oct 4. J Exp Med. 2010. PMID: 20921286 Free PMC article.
-
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.Cancer Cell. 2024 Jul 8;42(7):1202-1216.e8. doi: 10.1016/j.ccell.2024.05.025. Epub 2024 Jun 20. Cancer Cell. 2024. PMID: 38906155
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials